Get all premium features to the best stock analysis tool

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa (RP) has undergone subretinal implantation. DSP-3077 is an investigative regenerative cell therapy that leverages allogeneic retinal sheets derived from induced pluripotent stem (iPS) cells. This Phase 1/2a, open-label, single-arm, uncontrolled, dose-escalation study (NCT06891885) is evaluating tw.

Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has been Certified™ by Great Place To Work® for July 2026-2027. The prestigious award is based entirely on what current employees say about their experience working at SMPA. This year, 89% of company employees said SMPA is a great place to work – compared to just 57% of employees at the average U.S. company. “When employees have a positive perception of the company, it becomes a powerful driver of.